The antidepressant fluvoxamine (Luvox) may prevent hospitalization and death in outpatients with COVID-19, new research suggests. Results from the placebo-controlled, multisite, phase 3 TOGETHER trial showed that in COVID-19 outpatients at high risk for complications, hospitalizations were cut by 66% and deaths were reduced by 91% in those who tolerated fluvoxamine. "Our [...]
The US Food and Drug Administration (FDA) has approved a high-dose naloxone injection product for the emergency treatment of opioid overdose. ZIMHI from Adamis Pharmaceuticals is administered using a single-dose, prefilled syringe that delivers 5 mg of naloxone hydrochloride solution through intramuscular or subcutaneous injection. Naloxone is an opioid antagonist [...]
Johnson & Johnson thinks a longer-acting treatment against schizophrenia will help keep patients on their prescriptions and reduce their chances of a relapse. Now, with a FDA nod under its belt, the company is pushing Invega Hafyera as just the med to fit the bill. The FDA Wednesday approved J&J’s [...]
Background Precise cannabis treatment dosing remains a major challenge, leading to physicians’ reluctance to prescribe medical cannabis. Objective To test the pharmacokinetics, analgesic effect, cognitive performance and safety effects of an innovative medical device that enables the delivery of inhaled therapeutic doses of Δ9-Tetrahydrocannabinol (THC) in patients with chronic pain. [...]
The objective of this research was to develop and evaluate an evidence-based suicide attempt risk checklist [i.e., the Durham Risk Score (DRS)] to aid clinicians in the identification of individuals at risk for attempting suicide in the future. Methods and findings Three prospective cohort studies, including a population-based study from [...]
I cut myself for the first time today and I feel worse I'm up at 5 am writing this because I can't sleep and anxiety is keeping me up. I'm a 17 year old girl and cut myself with a blade for the first time today. I have cut myself [...]
According to well-placed recent reports, Biogen Inc withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer's drug, Aduhelm, that was submitted to medical journal JAMA. Biogen withdrew the paper as JAMA considered rejecting it unless edits were made, according to the report. (https://bit.ly/3f2zsvf) The U.S. [...]
There are multiple risk factors for self-harm, including a history of abuse, trauma, physical and mental illness, and bullying. Identifying these factors is a key part of prevention, ensuring that those at risk receive appropriate support as early as possible — but despite this, predicting who may end up engaging [...]
Three members of a US Food and Drug Administration (FDA) advisory committee are explaining why they do not support approval of the drug aducanumab (Biogen, Eisai) for the treatment of Alzheimer's disease (AD). G. Caleb Alexander, MD, Scott Emerson, MD, PhD, and Aaron Kesselheim, MD, JD, MPH, all serve on the [...]
An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials show. Dr Leslie Citrome For both disorders, BXCL501 showed "superiority over placebo" by meeting the primary endpoint of reduction of agitation as [...]